Research and Practice in Thrombosis and Haemostasis · 2017 · 44 citations · 22 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyHemostasisPharmacodynamicsAnticoagulant TherapyAnticoagulation TherapyAntithrombotic TherapyThrombin GenerationThrombosisThrombosis PreventionAnticoagulant Effects On Thrombin GenerationDirect Oral Anticoagulant MonitoringDirect Oral Anticoagulant TherapyDirect Oral Anticoagulants MonitoringEndogenous Thrombin PotentialMonitoring Of Anticoagulant TherapyThrombin Generation AssaysTime To Peak Thrombin
Essentials•The value of thrombin generation assay (TGA) in monitoring direct oral anticoagulants (DOAC) is not well defined.•TGA parameters were measured and correlated to DOAC levels in 10 healthy volunteers after oral intake of DOACs.•Lag time is the only sensitive TGA parameter across different DOACs, dabigatran, rivaroxaban and apixaban.•Endogenous thrombin potential had weak correlation with DOAC levels and not suitable as stand‐alone parameter.BackgroundThere are clinical situations where monitoring direct oral anticoagulants (DOACs) may be useful. The clinical application of thrombin generation assay (TGA) in monitoring the effect of DOACs has not been well established. An ex vivo study was performed to systematically evaluate the anticoagulant effect of dabigatran, rivaroxaban and apixaban on each individual TGA parameter through serial measurements over time to assess suitability of these parameters for monitoring the anticoagulant effect of DOACs.MethodsTen healthy volunteers were given oral dabigatran 150 mg, rivaroxaban 20 mg, or apixaban 10 mg once. TGA parameters lag time, endogenous Thrombin potential (ETP), and thrombin peak height, time to peak, and velocity index were measured at times 0, 2, 4, and 24 hours after intake of DOAC. TGA parameters and DOAC concentrations were correlated.ResultsThe lag time was significantly correlated with all DOAC concentrations (r≥ .81, P< .0001 for all). Thrombin peak height best correlated with direct Factor Xa inhibitor (FXa) concentrations in nonlinear fashion (R² ≥ .87). ETP was weakly correlated with DOAC levels (r≤ .68). Besides lag time, the other TGA parameters were not significantly altered over time by dabigatran.ConclusionLag time was the only sensitive TGA parameter across the different classes of DOACs evaluated. Thrombin peak height was strongly correlated to FXa inhibitor concentrations and potentially a useful parameter to monitor FXa inhibitors at low concentrations. ETP had a weak correlation with achieved DOAC concentrations and is likely less suitable for assessment of DOAC effect as a stand‐alone parameter.
22
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Deborah Siegal, John T. Curnutte, Stuart J. Connolly et al. · New England Journal of Medicine · 2015 · 1K citations · Full text
Paul Reilly, Thorsten Lehr, Sebastian Haertter et al. · Journal of the American College of Cardiology · 2013 · 826 citations
Medicine, Cardiology, Pharmacology +17
Impact of dabigatran on a large panel of routine or specific coagulation assays
Séverine Robert, C Chatelain, Jonathan Douxfils et al. · Thrombosis and Haemostasis · 2012 · 322 citations
Medicine, Hematology, Pharmacology +17